Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
Physician's Weekly,
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9…
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9…
Benefits seen across baseline LDL-C levels of 50 to 125 mg/dL Even post-acute coronary syndrome (ACS) patients with low…
Why is cholesterol so much more controversial than the other cardiac risk factors? A review of cholesterol’s troubled and…
By Rhodes…